Key points {#Sec1}
==========

In Japan, one third of the patients received antibiotics within 1 h and three fourths within 3 h of sepsis recognition.Our descriptive results do not support early antibiotic administration, i.e., within 1 h after diagnosis, for reducing in-hospital mortality in patients with severe sepsis and septic shock.

Background {#Sec2}
==========

Time to antibiotic administration is a key element in sepsis care, and the Surviving Sepsis Campaign (SSC) guidelines (2004, 2008, 2012, and 2016) have repeatedly recommended initiating empirical broad-spectrum therapy within 3 h from triage or sepsis recognition \[[@CR1]--[@CR4]\]. However, the updated 2018 SSC guidelines recommend a 1-h window for antibiotic administration following the recognition of sepsis as a reasonable approach \[[@CR5]\]; this update has been significantly debated, and it remains controversial \[[@CR6]\]. Although it would be impossible to argue against appropriate and timely antibiotic therapy for sepsis considering its time-sensitive nature, sepsis is different from other emergent conditions such as acute coronary syndrome, stroke, or trauma. Specifically, its recognition by healthcare providers within 1 h of presentation may be difficult to achieve in real-life settings because of vague presenting symptoms and the fact that its exact onset is mostly unobservable. Further, the only randomized controlled trial (RCT) that evaluated early antibiotic use in patients with suspected infection failed to reduce mortality, although this was in the pre-hospital setting \[[@CR7]\].

We prospectively evaluated the characteristics and management of patients with severe sepsis in the Focused Outcomes Research in Emergency Care in Acute Respiratory Distress Syndrome, Sepsis, and Trauma (FORECAST) study in Japan \[[@CR8]\]. We then used the FORECAST database to describe the association between time to antibiotic administration and outcomes in patients with severe sepsis and septic shock treated in real-world clinical settings.

Methods {#Sec3}
=======

The study protocol was reviewed and approved by the ethics committee of all participating institutions in the Japanese Association for Acute Medicine (JAAM) study group, Japan (IRB No.014-0306 on Hokkaido University, a representative institution for FORECAST). Obtaining an informed consent from a study participant was waived under the approval of the ethics committees.

Design and setting {#Sec4}
------------------

This is a predefined secondary analysis of the FORECAST study. We predefined the secondary analyses when we set variables of the FORECAST study. It selected a cohort of patients with severe sepsis and septic shock who were registered in the FORECAST study, which was a multi-center, prospective data collection study on acutely ill patients that included those with acute respiratory distress syndrome, sepsis, and trauma. The FORECAST study obtained data from patients admitted to 59 intensive care units (ICUs) in Japan and was conducted from January 1, 2016, to March 31, 2017.

Participants {#Sec5}
------------

We included adult patients (≥ 16 years) diagnosed with severe sepsis and septic shock based on the Sepsis-2 criteria published in 2003 \[[@CR9]\] and admitted to the ICU. The exclusion criteria were unfavorable sustained life-care or post-cardiopulmonary arrest resuscitation status at the time of sepsis recognition, missing data on antibiotic timing or in-hospital mortality, or time to antibiotic use \> 1440 min.

Data collection {#Sec6}
---------------

Relevant patient data, originally compiled by the FORECAST investigators, were obtained from the FORECAST database. Hospital information obtained included number, specialty, type of facility and staff, number of patients, and number of beds. Patient data, collected as part of the clinical workup, included demographic characteristics of patients, organ dysfunctions, sepsis-related severity scores, time to antibiotic administration, in-hospital mortality, 28-day mortality, ICU-free days, ventilator-free days (VFD), and length of hospital stay. Additionally, we obtained data on compliance with established sepsis care bundles, such as measurement of the initial serum lactate levels within 3 h.

Data definitions {#Sec7}
----------------

Sepsis care bundles were defined according to the SSC guidelines (2012) \[[@CR3]\] as to whether all bundle elements were achieved within the appropriate time frame (i.e., 3 or 6 h) and if they adhered to indications (i.e., septic shock or lactate level \> 4 mmol/L). For all patients, protocol initiation time was defined as the time of sepsis recognition at the emergency department (ED), ward, or ICU. Sepsis recognition was a clinical judgment, wherein a physician-in-charge had suspected sepsis at the initial evaluation. Timestamp was recorded in the database by a physician-in-charge. Patients with antibiotic before arrival were recognized as patients with infection but not sepsis. After arrival, time would start when a physician-in-charge recognized a patient with sepsis. Time from sepsis recognition to initiation of antibiotics (time to antibiotic) was divided into six groups defined as 0--60, 61--120, 121--180, 181--240, 241--360, and 361--1440 min. Septic shock was defined based on the Sepsis-2 criteria \[[@CR9]\], and VFD was defined as the number of days within the first 28 days after hospital admission during which a patient was able to breathe without a ventilator. VFD for patients who died during the study period was listed as 0. ICU-free days were similarly calculated.

Analysis {#Sec8}
--------

The primary outcome was in-hospital mortality. Secondary outcomes were VFD and ICU-free days. The exposure was time to antibiotic. Because the missing data were low, no assumptions were made for this factor.

Descriptive statistics included frequency and percentage for categorical variables and mean ± standard deviation (SD) or medians and interquartile range (IQR) for continuous variables, as appropriate. We compared baseline characteristics and outcomes among patients with severe sepsis in the six time to antibiotic therapy groups (0--60, 61--120, 121--180, 181--240, 241--360, and 361--1440 min) using analysis of variance, Kruskal-Wallis test or chi-square test, as required.

The impact of antibiotic timing on risk-adjusted hospital mortality was estimated using the generalized estimating equation (GEE) model with an exchangeable within-group correlation matrix where the hospital was the panel or grouping variable. The following covariates were specified a priori based on clinical experience and prior studies: patient age, gender, admission source (ED, ward, or in ICU), Charlson comorbidity index (CCI), antibiotic use before arrival, site of infection (e.g., lung, abdomen, urinary tract, soft tissue, central nerve system, or blood stream-related), sepsis-related organ failure assessment (SOFA) score, and intravenous fluid bolus completed within 3 h (30 mg/kg crystalloid). We also performed the same analysis after replacing time to antibiotic as a continuous variable. In a subgroup analysis, we stratified patients with septic shock and those from only ED based on hospital admission source and analyzed these subgroups as described in the primary analysis \[i.e., the GEE model adjusted patient age, gender, CCI, antibiotic use before arrival, site of infection, SOFA score, and intravenous fluid bolus completed within 3 h (30 mg/kg crystalloid)\].

All statistical analyses were performed using Stata software version 15.1 (StataCorp, TX, USA).

Results {#Sec9}
=======

We recruited 1184 patients with severe sepsis who were admitted to ICUs at participating institutions during the FORECAST study period. Of these, 60 patients were excluded because of missing data on the timing of antibiotic administration (*n* = 11) or in-hospital mortality (*n* = 33) or because the time to antibiotic was greater than 1440 min. Of the remaining 1124 participants who were admitted to 54 hospitals, 30.5% of the patients received antibiotics within 1 h, and 73.9% of the patients received antibiotics within 3 h. Overall, the median time to antibiotic administration was 102 min (IQR, 55--189), and compared with patients diagnosed in the ED \[90 min (IQR, 48--164 min)\], time to antibiotic administration was shortest in patients diagnosed in ICUs \[60 min (39--180 min)\] and longest in patients who had been transferred from wards \[120 min (62--226 min)\], implying that patients diagnosed in the ED or the ICU received antibiotics earlier than those in the ward.

Baseline characteristics, categorized based on the timing of antibiotic administration, are detailed in Table [1](#Tab1){ref-type="table"}. The 0--60, 61--120, and 121--180 min groups received lower pre-antibiotic therapy, such as oral medicines for infection, than the other groups. The 0--60, 61--120, and 121--180 min groups were also more likely to achieve the 3-h bundle, such as obtaining blood cultures and intravenous fluid bolus than the other groups. Table 1Baseline characteristics of patients with severe sepsis and septic shock according to the timing of antibiotic administrationTime to antibiotic use (min)*p* value0--6061--120121--180181--240241--360361--1440Number of patients, *n*11243433271619410396Age at admission in years, median (IQR)73 (65--82)73 (63--81)75 (66--82)68 (58--78)74 (67--81)74 (63--83)0.035Gender, *n* (% male)196 (57.1)190 (58.1)102 (63.4)65 (69.2)65 (63.1)57 (59.4)0.295Admission source, *n* (%)ED210 (61.4)194 (59.3)94 (58.4)45 (47.9)56 (54.4)32 (33.3)\< 0.01ICU22 (6.4)8 (2.5)3 (1.9)3 (3.2)3 (2.9)4 (4.2)Ward110 (32.2)125 (38.2)64 (39.8)46 (48.9)44 (42.7)60 (62.5)Carlson comorbidity index, median (IQR)1 (0--2)1 (0--2)1 (0--2)1 (0--2)1 (0--2)1 (0--2)0.8543Antibiotic use for infection before arrival, *n* (%)112 (32.8)100 (30.8)51 (31.9)41 (44.1)42 (41.6)55 (57.3)\< 0.01Suspected site of infection, *n* (%)Lung91 (26.5)102 (31.2)62 (38.5)31 (33.0)34 (33.0)31 (32.2)0.003Abdomen102 (29.7)69 (21.1)34 (21.1)22 (23.4)30 (29.1)32 (33.3)Urinary tract73 (21.3)76 (23.2)27 (16.8)13 (13.8)12 (11.7)11 (11.5)Soft tissue and wound32 (9.3)44 (13.5)16 (9.9)15 (16.0)12 (11.7)5 (5.2)Central nervous system8 (2.3)2 (0.6)3 (1.9)4 (4.3)4 (3.9)0 (0)Blood stream-related12 (3.5)18 (5.5)10 (6.2)7 (7.5)6 (5.8)10 (10.4)Others25 (7.3)16 (4.9)9 (5.6)2 (2.1)5 (4.9)7 (7.3)Positivity of blood cultures, *n* (%)192 (56.3)162 (49.7)86 (54.1)50 (53.2)60 (58.3)52 (54.2)0.561Septic shock, *n* (%)215 (62.7)207 (63.3)94 (58.4)61 (64.9)69 (67.0)57 (59.4)0.735Mechanical ventilation, *n* (%)142 (42.3)129 (40.6)58 (37.2)36 (39.1)43 (42.2)38 (40.9)0.932Organ dysfunction on arrivalHypotension, *n* (%)193 (56.3)178 (54.4)74 (46.0)59 (62.8)65 (63.1)46 (47.9)0.029Hyperlactatemia (\> 2 mmol/L), *n* (%)240 (70.0)214 (65.4)119 (73.9)61 (64.9)69 (67.0)45 (46.9)\< 0.01Acute kidney injury (creatinine \> 2 mg/dL), *n* (%)134 (39.1)118 (36.1)64 (39.8)34 (36.2)37 (35.9)37 (38.5)0.946Acute lung injury, *n* (%)115 (33.5)120 (36.7)72 (44.7)37 (39.4)36 (35.0)37 (38.5)0.269Hyperbilirubinemia (\> 2.0 mg/dL), *n* (%)58 (16.9)48 (14.7)31 (19.3)17 (18.1)17 (16.5)21 (21.9)0.62Thrombocytopenia (\< 100,000/μL), *n* (%)104 (30.3)91 (27.8)43 (26.7)29 (30.9)31 (30.1)28 (29.2)0.951Coagulopathy (INR \> 1.5), *n* (%)70 (20.4)61 (18.7)25 (15.5)18 (19.2)15 (14.6)18 (18.8)0.72Number of organ dysfunction, median (IQR)2 (2--4)2 (1--3)2 (2--3)3 (2--4)2 (1--3)2 (1--3)0.1893APACHE II score, median (IQR)22 (17--30)22 (16--28)23 (18--31)21 (16--29)25 (19--32)24 (18--29)0.1613SOFA score, median (IQR)9 (6--11)8 (6--11)9 (5--11)8 (6--11)9 (6--12)8 (5--11)0.7155Blood cultures before antibiotics completed within 3 h, *n* (%)318 (93.0)310 (95.4)148 (91.9)83 (88.3)94 (91.3)78 (81.3)\< 0.01Intravenous fluid bolus completed within 3 h (30 mg/kg crystalloid), *n* (%)No37 (10.9)50 (15.3)32 (20.1)21 (22.6)22 (21.4)27 (28.1)0.001Yes212 (62.4)185 (56.6)75 (47.2)43 (46.2)53 (51.5)40 (41.7)Not indicated91 (26.8)92 (28.1)52 (32.7)29 (31.2)28 (27.2)29 (30.2)Serum lactate obtained, *n* (%)331 (96.8)321 (98.2)153 (95.0)92 (97.9)99 (96.1)92 (95.8)0.483Entire 3-h bundle if indicated (*n* = 796), *n*/total (%)194/249 (77.9)170/234 (72.7)67/107 (62.6)25/64 (39.1)33/75 (44.0)21/67 (31.3)\< 0.01Missing data: admission source = 1, antibiotic use before arrival = 8, blood cultures = 5, mechanical ventilation = 27, APACHE II score = 122, SOFA score = 171, blood cultures before antibiotics completed within 3 h = 3, intravenous fluid bolus completed within 3 h (30 mg/kg crystalloid) = 6, serum lactate obtained = 1*ED* emergency department, *ICU* intensive care unit, *PT-INR* prothrombin time to international normalized ratio, *APACHE II* Acute Physiology and Chronic Health Evaluation II, SOFA sepsis-related organ failure assessment

Overall crude mortality was 23.4% in the study population. Crude mortalities were 27.7% and 16.2% among patients with and without shock, respectively. Patients received antibiotics within the first 60 min had the highest rates of mortality (28.0%) and risk-adjusted mortality \[28.7% (95% CI 23.3--34.1); Table [2](#Tab2){ref-type="table"}, Fig. [1](#Fig1){ref-type="fig"}\], whereas that of patients administered with antibiotics between 61 and 120 min had the lowest (20.2%) and risk-adjusted mortality rates \[21.6% (95% CI 16.5--26.6)\]. Importantly, mortality was different only between patients in the 0--60 and 61--120 min groups. In addition, time to antibiotics as a continuous variable was not related to mortality, either (odds ratio 0.999 \[0.997--1.000; *P* = 0.152\]). Subgroup analysis yielded a crude mortality rate of 27.7% in patients with septic shock, and patients in the 0--60 min group continued to have the highest mortality (31.6%) and risk-adjusted mortality rates \[30.0% (95% CI 23.5--36.5)\], whereas those patients administered with antibiotics between 361 and 1440 min were the lowest \[21.6% (95% CI 11.1--32.0)\]. In addition, the subgroup analysis yielded a crude mortality rate of 21.9% in the ED patients, and patients in the 0--60 min group continued to have the highest mortality (29.1%) and risk-adjusted mortality rates (27.9% \[95% CI 21.1--34.6\]), whereas that in patients administered with antibiotics between 361 and 1440 min was the lowest \[12.8% (95% CI 5.7--25.0)\]. Table 2Outcomes of patients with severe sepsis and septic shock according to the time to antibioticsTime to antibiotic use (min)*p* value0--6061--120121--180181--240241--360361--1440Crude in-hospital mortality among all patients, *n*/total (%), *n* = 112496/343 (28.0)66/327 (20.2)35/161 (21.7)19/94 (20.2)26/103 (25.2)21/96 (21.9)0.219Crude in-hospital mortality among patients with septic shock, *n*/total (%), *n* = 70368/215 (31.6)47/207 (22.7)27/94 (28.7)16/61 (26.2)21/69 (30.4)16/57 (28.1)0.466Crude in-hospital mortality among patients from ED, *n*/total (%), *n* = 63161/210 (29.1)36/194 (18.6)14/94 (14.9)8/45 (17.8)15/56 (26.8)4/32 (12.5)0.022Adjusted in-hospital mortality among all patients (95% CI)^a^, *n* = 94928.7 (23.3--34.1)\*21.6 (16.5--26.6)\*23.2 (16.4--30.0)20.4 (12.1--28.7)20.5 (12.6--28.5)21.1 (12.5--29.7)Adjusted in-hospital mortality among patients with septic shock (95% CI)^a^, *n* = 61530.0 (23.5--36.5)22.3 (16.1--28.5)28.5 (19.3--37.6)27.4 (15.9--38.9)25.1 (15.2--35.1)21.6 (11.1--32.0)Adjusted in-hospital mortality among patients from ED (95% CI)^a^, *n* = 50327.9 (21.1--34.6)\*18.4 (12.2--24.5)\*17.8 (9.3--26.2)17.2 (5.4--28.9)24.1 (12.2--36.0)12.8 (5.7--25.0)Crude 28-day mortality, *n*/total (%), *n* = 111275/338 (22.2)55/325 (16.9)26/159 (16.4)15/92 (16.3)22/103 (21.4)17/95 (17.9)0.445ICU-free days, median (IQR), *n* = 90220 (12--24)20 (13--24)20 (9--23)18 (6--24)18 (10--24)19 (1023)0.3522Ventilator-free days21 (0--28)21 (8--28)22 (0--28)20 (0--27)21 (0--27)20 (0--28)0.3947Length of hospital stay26 (13--46)22 (11--43)26 (13--49)21 (13--38)25 (12--54)29 (13--48)0.4827*ED* emergency department, *CI* confidence interval, *ICU* intensive care unit, *IQR* interquartile range\*\< 0.05^a^Adjusted by age, gender, admission source (emergency department, ward, or in intensive care unit), CCI, antibiotic use before arrival, site of infection (e.g., lung, abdomen, urinary tract, soft tissue, central nerve system, or blood stream-related), SOFA score, and intravenous fluid bolus completed within 3 h (30 mg/kg crystalloid) Fig. 1Adjusted in-hospital mortality according to the timing of antibiotic administration among patients with severe sepsis and septic shock. Adjusted by age, gender, admission source (emergency department, ward, or in intensive care unit), CCI, antibiotic use before arrival, site of infection (e.g., lung, abdomen, urinary tract, soft tissue, central nerve system, or blood stream-related), SOFA score, and intravenous fluid bolus completed within 3 h (30 mg/kg crystalloid)

Discussion {#Sec10}
==========

Summary {#Sec11}
-------

In emergency medical centers in Japan, one third of patients receive antibiotics within 1 h and three quarters within 3 h of sepsis recognition. Although we have found high levels of adherence to the sepsis care bundle (2012) during the study period, we were unable to show a linear relationship between the timing of antibiotic administration, such as within 1 h or 3 h after sepsis recognition, and in-hospital mortality among patients with severe sepsis and septic shock.

Comparison with previous studies {#Sec12}
--------------------------------

Although previous studies have shown that a delay in antibiotic administration is associated with a higher in-hospital mortality rate \[[@CR10]--[@CR14]\], our findings from a prospective observational study obtained data of antibiotic administration timing do not support their results. Neither prospective nor retrospective observational data can establish causation, and discrepancies between these results only raise further questions. Interestingly, a meta-analysis of studies regarding the relationship between antibiotic administration timing and mortality found no significant benefit after administering antibiotics within 1--3 h from triage or sepsis recognition in comparison with administration at a later timing \[[@CR15]\], and a RCT of providing antibiotics to patients with suspected sepsis in the ambulance did not show improved survival \[[@CR7]\]. Nonetheless, these previous studies \[[@CR7], [@CR10]--[@CR13]\] and the present study have three major problems: (1) understanding the clinical courses of sepsis, including its onset; (2) stratification of sepsis severity and cognate adjustments to treatment strategies, e.g., rapid treatments; and (3) establishing correlation or causation in sepsis care bundle studies.

Sepsis is different from other time-dependent and emergent conditions such as acute coronary syndrome because its precise onset is difficult to establish and the lack of a specific diagnostic marker makes recognition problematic. Three phases in the clinical course of sepsis are recognized: (A) time from onset of infection to a detectable condition, (B) time from a detectable condition to diagnosis, and (C) time from diagnosis to antibiotic administration (time to antibiotic), and although phases A and B are significantly shorter in other time-dependent emergent conditions, the duration of these two phases varies considerably in sepsis. Furthermore, it is difficult to focus only on phase C to reduce mortality in sepsis as other variables that can affect outcomes include the timestamp of antibiotic initiation (time zero) and patient location, as seen in previous studies \[[@CR15]\] and in our study. Similar to other studies, we defined time zero as the time of sepsis recognition, although it is a subjective choice \[[@CR15]\], because the clinical course of each patient would differ based on the presenting symptoms, even if triage at ED is chosen as a reliable time zero point \[[@CR16]\]. Thus, detection of sepsis and antibiotic initiation are equally important as delays in appropriate antibiotic therapy are more likely to occur in patients with complex or atypical presentations who are also more likely to harbor drug-resistant organisms \[[@CR17]\]. Moreover, reports show that inter-hospital transfer delayed the administration of initial antibiotics, although prognosis was not different \[[@CR18]\]. Similar to previous reports, our patients included not only those presenting to ED but also those being transferred from other hospitals \[[@CR15]\], and it is essential to disentangle such complicated definitions of time zero and locations in each study before direct comparisons can be made among these studies.

Sepsis severity stratification and adjustment with rapid treatment may have been insufficient in previous and our studies regarding time to antibiotic, and conflating sepsis and septic shock may also be a confounder. Although 63% of the patients in our study presented with shock, we could not find any association between earlier time to antibiotic and reduced mortality in all participants. Recent studies have demonstrated a weak association between time to antibiotic therapy and mortality in all cohorts (a relatively mild state in comparison with our cohort), although a large significant association between delays in antibiotic administration and higher mortality rates in patients with septic shock \[[@CR10], [@CR11]\]. Further, an RCT of administering antibiotics to patients with suspected sepsis in the ambulance also included many patients without shock \[[@CR7]\]. In the study, it notes that even patients in the control group received antibiotics quite early and that the patients were treated with low risk (mortality rate 8%). This is quite a different population compared with that in the hospital setting. Indeed, severity adjustment is difficult in sepsis studies because sepsis includes complicated etiologies, various presentations, and severities compared with other medical emergencies \[[@CR19]\]. Nevertheless, in our study, we used fewer variables to adjust severity in comparison with previous studies owing to the limitations of our database \[[@CR12], [@CR13]\]. Previous studies have reported higher crude mortality rates in patients administered with antibiotics in the first hour, which then declined over time; however, severity adjustment reversed the relationship between time to antibiotic and mortality \[[@CR12], [@CR13]\]. Our study may also have been under-adjusted for severity because the sample size was relatively smaller and covariates were fewer than those in previous studies \[[@CR10]--[@CR13]\].

Next, we must consider whether this relationship between time to antibiotic and mortality causative or only a correlation, given that all other components of the sepsis care bundle may be potentially physiologically effective along with time to antibiotic and that the effectiveness of each component remains controversial in various settings \[[@CR10], [@CR20], [@CR21]\]. Adherence to the sepsis care bundle also varies in each setting \[[@CR8], [@CR10], [@CR22], [@CR23]\]. For example, in a study among patients who received antibiotics as they met the criteria for severe sepsis, a relatively high compliance rate for the sepsis care bundle was reported if sepsis was definitively diagnosed (with diagnosis code) compared with undiagnosed sepsis (without diagnosis code) \[[@CR22]\]. In our study, the 0--60, 61--120, and 121--180 min groups were more likely to comply with the 3-h bundle, compared with the others. Conversely, the prognosis may have been good in patients who had been diagnosed early and in those who were administered with antibiotics early \[[@CR10]--[@CR13]\], implying that diagnosing sepsis may be more important than initiating the sepsis care bundle. Further, all components of the bundle should be investigated in future studies that focus on the relationship between time to antibiotic and trigger of initiation.

Possible explanations and implications {#Sec13}
--------------------------------------

Medical staff intuitively understands that the early use of appropriate antibiotics is an important modifiable factor. However, optimal timing and its effectiveness remain unclear after a widespread implementation of the sepsis protocol in developed countries such as Japan. Although there is no doubt that sepsis care bundle components, such as time to antibiotic, play a role in the arising importance of treatment speed, a similar situation arose when early goal-directed therapy was debated \[[@CR24], [@CR25]\].

In this study, patients who received antibiotics within the first hour had the highest mortality despite the greatest compliance with the entire 3-h bundle. This may be because of the severity at presentation, detecting antibiotic use within the first hour, or an obvious septic state. Alternatively, very early antibiotic use (within 1 h) may lead to unfavorable outcomes; although, this does not seem likely as all the patients would have had a sepsis state for some time before the point of recognition \[[@CR26]\]. Furthermore, indiscriminate and rapid use of broad-spectrum antibiotics in all patients may be potentially harmful \[[@CR27], [@CR28]\], as it may lead to adverse events; however, there are only few reports on adverse events of rapid use of antibiotics. Incorrect diagnosis of sepsis may lead to a delay in administering other useful treatments or appropriate source control despite the use of broad-spectrum antibiotics \[[@CR17]\].

Although there may be a linear relationship between early time to antibiotic therapy and better prognosis in sepsis, it is presumably weak. Moreover, similar to the previous study report, our results showed that earlier time to antibiotic therapy was related to better outcomes in ED patients \[[@CR14]\] when we excluded patients who received antibiotics within 1 h. Otherwise, focusing on the rapid use of antibiotics may lead to misdiagnosis of the site of infection, which is related to poor outcomes \[[@CR28]\]. Sepsis treatment and care involve components other than the time to antibiotic, and while this does not mean that rapid treatments are not good, most physicians intuitively recognize the need for it. Thus, timely antibiotic administration to patients with sepsis should remain one of the key elements in the sepsis care bundle, regardless of time restriction.

Limitations {#Sec14}
-----------

This study has several limitations. First, controlling for confounders may have been insufficient, as there are potential unknown confounders not available to us. Antibiotic initiation can be determined not only based on the patient's severity but also on unknown factors that are difficult to be quantified. Second, there were patients who were using antibiotics before arrival. We have adjusted antibiotic use before arrival as a covariate in the GEE models. Moreover, the results did not change significantly even if patients with antibiotic usage before arrival were excluded. Third, there may be an indication bias as antibiotics may have been prescribed within the first hour only in patients with severe (non-survivable) presentation. However, we found that the results did not change even if patients who died within 1, 2, or 3 days were excluded from the analysis, suggesting that it may be difficult to show differences in practice quality between patients presenting with considerably mild and considerably severe symptoms \[[@CR7]\]. Forth, there may have been a social desirability bias, as physicians usually wish to be evaluated as having responded to critical patients first. Fifth, there may have been a ceiling effect with respect to severity scores, because our study population was more severely ill than those in previous studies. Sixth, the timestamp of protocol initiation was defined as at the time of sepsis recognition, which is relatively later than the time of triage at ED. Our study may have only shown a relationship between time to antibiotic and in-hospital mortality if sepsis recognition occurred early in the course of the disease. Seventh, we did not have data about the appropriateness of antibiotic. However, as the first FORECAST paper \[[@CR8]\] showed, 84% of patients received broad-spectrum antibiotics within 3 h. Most patients at least adhered to empiric antibiotics based on the guideline. In addition, carbapenem was most commonly used after initial diagnoses (55%) followed by tazobactam/piperacillin (21%) and vancomycin (18%). Thus, the important pathogens would have been covered by the chosen antibiotics even if antibiotic-resistant pathogens were present. Finally, the descriptive nature of the study could not completely identify the causal inference between the observed time to antibiotic and in-hospital mortality. In this study, we described sepsis care and implementation of sepsis bundle in Japan as one of the high adherence countries of the sepsis guideline. Our results suggested that this relationship is still controversial, and RCT of this topic should be studied further.

Conclusions {#Sec15}
===========

Our prospective study failed to show a difference in in-hospital mortality based on the timing of antibiotic administration. Future studies are needed to prove or refute these results among patients with sepsis or septic shock.
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